---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-026162"
form_type: "8-K"
ticker: "AMIX"
cik: "0001617867"
company_name: "Autonomix Medical, Inc."
filed_at: "2024-08-13T23:59:59+00:00"
generated_at: "2026-05-31T09:43:26.972486+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Autonomix Medical reports Q1 FY2025 net loss $2.7M, positive 7-day pain relief data from lead-in patients

## Summary
- Net loss $2.7M vs $0.9M YoY; cash $6.8M as of June 30, 2024.
- G&A $1.8M (up $1.3M) and R&D $1.0M (up $0.6M) driven by compensation and clinical costs.
- 60% of first five lead-in patients had mean 6.33 VAS pain reduction (from 8.0 to 1.67) at 7 days.
- Appointed Brad Hauser CEO; licensed RF Innovations' FDA-cleared Apex 6 ablation generator.
- Expects topline PoC trial data 1H CY2025, FDA de novo submission 2026, clearance 2027.

## SEC filing metadata
- accession: 0001437749-24-026162
- form_type: 8-K
- ticker: AMIX
- cik: 0001617867
- company_name: Autonomix Medical, Inc.
- filed_at: 2024-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1617867/000143774924026162/0001437749-24-026162-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1617867/000143774924026162/amix20240812_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-026162
- JSON: https://secwatch.observer/filing/0001437749-24-026162.json
- Plain text: https://secwatch.observer/filing/0001437749-24-026162.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.